Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/cncy.22748 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Management of thyroid tumors diagnosed cytologically as follicular neoplasms in a high-volume center: utility of a scoring system using serum thyroglobulin level, tumor size, ultrasound testing, and cytological diagnosis.
Endocr J
October 2024
Department of Internal Medicine, Kuma Hospital, Hyogo 650-0011, Japan.
Managing thyroid nodules diagnosed cytologically as follicular neoplasms (FN) is challenging for patients and clinicians. Gene panel testing was recently introduced to determine the management strategy for FN; however, it is unavailable in Japan. In this study, we assessed FN management.
View Article and Find Full Text PDFCatching the Silent Culprits: TERT Promoter Mutation Screening of Minimally Invasive Follicular and Oncocytic Thyroid Carcinoma in Clinical Practice.
Endocr Pathol
December 2024
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Article Synopsis
- * In a study of 84 minimally invasive follicular and oncocytic thyroid carcinomas, TERT promoter mutations were found in 11.9% of cases, with mutated tumors associated with older patient age but no other significant clinical differences.
- * Although TERT mutations did not correlate with poor clinical outcomes, reflex testing for these mutations may be beneficial for risk assessment in low-risk tumors, despite the unclear clinical advantage.
WHO 2022 updates on follicular cell and c-cell derived thyroid neoplasm.
J Med Life
January 2024
Department of Pathology, Sharda Hospital, Greater Noida, India.
The latest edition of the WHO Classification of thyroid tumors was released in 2022 and incorporates novel concepts vital to patient management. Thyroid follicular nodular disease is a term used to collectively represent a wide variety of benign and non-neoplastic lesions, including both clonal and non-clonal proliferations that manifest clinically as multinodular goiter. Thyroid neoplasms develop from follicular cells and can be either benign, low-risk, or malignant.
View Article and Find Full Text PDFMolecular Pathology of Thyroid Tumors: Essential Points to Comprehend Regarding the Latest WHO Classification.
Biomedicines
March 2024
Department of Cytology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan.
In 2022, the new WHO Classification of Endocrine and Neuroendocrine Tumors, Fifth Edition (beta version) (WHO 5th), was published. Large-scale genomic analyses such as The Cancer Genome Atlas (TCGA) have revealed the importance of understanding the molecular genetics of thyroid tumors. Consequently, the WHO 5th was fundamentally revised, resulting in a systematic classification based on the cell of origin of tumors and their clinical risk.
View Article and Find Full Text PDFIncidental thyroid carcinoma in an endemic goiter area in Italy: histopathological features and predictors of a common finding.
Endocrine
May 2024
Department of Health Sciences, University of "Magna Græcia" Catanzaro, 88100, Catanzaro, Italy.
Purpose: The occurrence and histopathological features of incidental thyroid carcinoma (ITC) vary considerably among populations from different geographical regions. The aim of this study is to assess the prevalence and histopathological characteristics of ITC in patients who underwent thyroid surgery for apparently benign thyroid diseases in an endemic goiter area in Italy.
Methods: A total of 649 consecutive patients (531 females and 118 males; mean age, 52.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!